GoldenGolden
Advanced Search
Freenome

Freenome

Freenome is a San Francisco-based company which uses genetic analysis for early cancer detection and risk assessment.

Freenome is a biotechnology company that develops technology for early cancer diagnosis. It was founded in 2014.

Product

The company develops blood tests that are capable of early-stage cancer detection. It uses a multinomics platform which is comprised of various technologies, such as machine learning that is trained cancer-positive blood samples and other types of artificial intelligence. The platform can analyze the DNA, RNA, protein, and other biomarkers in the blood to detect cancer.

Timeline

August 2020
Freenome raises a $270,000,000 series C round from Novartis, Perceptive Advisors, Polaris Partners, RA Capital Management, Roche Venture Fund, Sands Capital Ventures, Section 32, Soleus Capital and T. Rowe Price.
May 26, 2020
Freenome announces initiation of the PREEMPT CRC Clinical Trial, a registrational study for the early detection and prevention of colorectal cancer using a multiomics blood test.
July 24, 2019
Freenome raises a $160,000,000 series B round from RA Capital Management.
July 2019
Freenome raises a $160,000,000 series B round from Andreessen Horowitz, Kaiser Permanente Ventures, Perceptive Advisors, Polaris Partners, RA Capital Management, Roche Venture Fund, T. Rowe Price and Verily Life Sciences.
March 2017
Freenome raises a $65,000,000 series A round from Andreessen Horowitz, Asset Management Ventures, Charles River Ventures, Data Collective, Founders Fund, Innovation Endeavors, Polaris Partners, The a16z Cultural Leadership Fund and s28 Capital.
June 2016
Freenome raises a $5,600,000 seed round from Andreessen Horowitz, DCVC, Founders Fund and Third Kind Venture Capital.
2015
Freenome was founded by Charles Roberts, Gabriel Otte, Gabriel Otte and Riley Ennis.

Funding rounds

People

Name
Role
LinkedIn

Christina Zeidan

Employee

Gabriel Otte

Founder

Michael Otte

Founder

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
May 26, 2020
BioSpace
Freenome , a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood draw, announced several new developments: initiating its PREEMPT CRC clinical trial; adding Gary Reedy, CEO of the American
Jonathan Shieber
July 24, 2019
TechCrunch
One of the major problems that technology companies working to find a cure for cancer need to solve is finding a safe, minimally invasive way to detect cancers early. Almost all cancer screening will eventually require a biopsy, but determining whether that's necessary in the early stages of cancer can mean the difference between life [...]

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.